Condensed Consolidated Statements of Operations (unaudited) - USD ($)		3 Months Ended		9 Months Ended
		Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Net sales		$ 58,419,270	$ 48,009,678	$ 169,155,294	$ 135,383,383
Cost of sales		30,239,482	22,469,952	79,494,367	63,710,703
Gross profit		28,179,788	25,539,726	89,660,927	71,672,680
Operating expenses:
Research and development		1,814,972	2,236,913	5,526,450	4,279,854
Marketing		4,510,223	10,792,331	27,507,937	20,077,293
Selling, general, and administrative		18,339,657	13,430,325	54,482,948	37,001,465
Write-off of acquired Drawbridge in-process research and development		0	0	0	1,563,015
Income (loss) from operations		3,514,936	(919,843)	2,143,592	8,751,053
Other (income) expense:
Interest income (expense), net		33,673	(29,089)	(27,998)	(392,990)
Guarantee fees		0	(141,949)	0	(421,220)
Change in fair value of warrant liability		37,926	2,212,554	566,906	902,528
Loss On Drawbridge Transaction		0	0	0	(165,998)
Other income (expense), net		391	39,473	44,485	77,616
Total other (income) expense, net		71,990	2,080,989	583,393	(64)
Income (loss) before income taxes and loss from equity interests in unconsolidated affiliates		3,586,926	1,161,146	2,726,985	8,750,989
Income tax expense		0	78,914	207,098	122,452
Net income (loss) before loss from equity interests in unconsolidated affiliates		3,586,926	1,082,232	2,519,887	8,628,537
Gain (Loss) from equity interests in unconsolidated affiliates		(14)	(131,390)	11,023	(3,304,496)
Net income (loss)		3,586,912	950,842	2,530,910	5,324,041
Net loss-non-controlling interests		(151,704)	(77,945)	(596,060)	(323,006)
Net income (loss) attributable to Thorne HealthTech, Inc.		3,738,616	1,028,787	3,126,970	5,647,047
Undistributed earnings attributable to Series E convertible preferred stockholders		0	553,078	0	5,171,338
Net income attributable to common stockholders		$ 3,738,616	$ 475,709	$ 3,126,970	$ 475,709
Earnings per share:
Basic	[1]	$ 0.07	$ 0.02	$ 0.06	$ 0.02
Diluted	[1]	$ 0.07	$ 0.01	$ 0.06	$ 0.01
Weighted average common shares outstanding:
Denominator for basic EPS-weighted average shares (B)	[1]	52,742,926	21,212,668	52,680,422	19,032,403
Diluted	[1]	52,742,926	51,222,522	52,921,051	50,327,893

[1] For the three and nine months ended September 30, 2022, 18.2 million and 17.3 million warrants and stock-based awards, respectively, were excluded from the computation of diluted EPS because the effect would have been anti-dilutive under the treasury stock method